Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Net Margin (2016 - 2025)

Avalo Therapeutics filings provide 9 years of Net Margin readings, the most recent being 23254.24% for Q4 2025.

  • On a quarterly basis, Net Margin fell 484851.0% to 23254.24% in Q4 2025 year-over-year; TTM through Dec 2025 was 15651.8%, a 768604.0% decrease, with the full-year FY2025 number at 132642.37%, down 12467661.0% from a year prior.
  • Net Margin hit 23254.24% in Q4 2025 for Avalo Therapeutics, down from 18405.73% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 9251.81% in Q3 2024 to a low of 23254.24% in Q4 2025.
  • Median Net Margin over the past 4 years was 1274.18% (2023), compared with a mean of 3588.02%.
  • The widest YoY moves for Net Margin: up 1146706bps in 2024, down -1697526bps in 2024.
  • Avalo Therapeutics' Net Margin stood at 29.68% in 2021, then plummeted by -4720bps to 1430.47% in 2023, then crashed by -1187bps to 18405.73% in 2024, then decreased by -26bps to 23254.24% in 2025.
  • The last three reported values for Net Margin were 23254.24% (Q4 2025), 18405.73% (Q4 2024), and 9251.81% (Q3 2024) per Business Quant data.